Search research articles
Contact Us
Filters
Showing results (81-90 of 164) with videos related to
Page
of 17
Sort By:
Journal for Immunotherapy of Cancer
|
January 30, 2019
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, et al.
Cancer
|
August 16, 2016
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno, Jean-Pascal Machiels, Lori Wirth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2017
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Christophe Massard, Kim Nguyen Chi, Daniel Castellano, et al.
Future Oncology (London, England)
|
January 30, 2026
JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC
Lillian L Siu, Barbara Burtness, Kevin Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2008
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial
Alain Ravaud, Robert Hawkins, Jason P Gardner, et al.
Lancet (London, England)
|
October 5, 2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, et al.
Cancer Chemotherapy and Pharmacology
|
November 1, 2016
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function
Analía Azaro, Jordi Rodón, Jean-Pascal Machiels, et al.
Investigational New Drugs
|
August 22, 2012
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J Pienta, Jean-Pascal Machiels, Dirk Schrijvers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2023
Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Natasha Honoré, Athenaïs van der Elst, Anna Dietz, et al.
Oncotarget
|
July 10, 2018
2'-deoxy-2'-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck
Lionel Mignion, Sandra Schmitz, Nicolas Michoux, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 164) with videos related to
Sort By:
Page
of 17
Journal for Immunotherapy of Cancer
|
January 30, 2019
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, et al.
Cancer
|
August 16, 2016
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno, Jean-Pascal Machiels, Lori Wirth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2017
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Christophe Massard, Kim Nguyen Chi, Daniel Castellano, et al.
Future Oncology (London, England)
|
January 30, 2026
JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC
Lillian L Siu, Barbara Burtness, Kevin Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2008
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial
Alain Ravaud, Robert Hawkins, Jason P Gardner, et al.
Lancet (London, England)
|
October 5, 2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, et al.
Cancer Chemotherapy and Pharmacology
|
November 1, 2016
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function
Analía Azaro, Jordi Rodón, Jean-Pascal Machiels, et al.
Investigational New Drugs
|
August 22, 2012
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J Pienta, Jean-Pascal Machiels, Dirk Schrijvers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2023
Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Natasha Honoré, Athenaïs van der Elst, Anna Dietz, et al.
Oncotarget
|
July 10, 2018
2'-deoxy-2'-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck
Lionel Mignion, Sandra Schmitz, Nicolas Michoux, et al.
Page
of 17